Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ziphius Vaccines N.V.
BioCentury | Oct 11, 2024
Management Tracks
Flagship takes on a third managing partner
Plus: New CEOs at Wheeler, Abalos, Oncovita, Syneos and Calluna, and updates from Phase, Ziphius and more
BioCentury | Sep 13, 2024
Data Byte
PanTera largest Belgian A round to date
Only nine other biotechs have raised over $25 million since 2015
BioCentury | Jul 5, 2024
Product Development
LNP innovation: tissue specificity, aided by AI
How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
BioCentury | Jan 14, 2023
Management Tracks
Senda hires O’Neill as CSO
Plus: Janssen’s Van Hoof to advise Ziphius, and updates from Nerviano and EDP
BioCentury | May 26, 2021
Regulation
May 25 Quick Takes: Moderna to submit pediatric COVID vaccine data to regulators in early June; plus FDA guidance on bispecifics, TG, Asylia, Pieris, Nordic, Ziphius and Kyma
Moderna Inc. (NASDAQ:MRNA) will be the next company to bring a COVID-19 vaccine forward for authorization in adolescents, with plans to submit data from the Phase II/III TeenCOVE study of its COVID-19
BioCentury | Mar 19, 2021
Product Development
Self-amplifying may be the next frontier in RNA therapies
Self-amplifying RNA brings a differentiated immune profile, enables lower doses
Items per page:
1 - 6 of 6